Navigation Links
The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers
Date:7/23/2014

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. 

Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies and plays a critical role in the viability, proliferation and migration of these cancer cells.

Idelalisib is an oral therapy indicated in combination with rituximab, a monoclonal antibody, for patients with relapsed or refractory CLL for whom rituximab alone would be considered appropriate therapy. In October 2013, a Phase 3 study evaluating idelalisib in combination with rituximab in previously-treated CLL patients not fit for standard chemotherapy was stopped early because interim analysis was showing significant improvement in progression-free survival as well as median overall survival compared to placebo plus rituximab.

Idelalisib was also approved today as a monotherapy for patients with relapsed FL and SLL who have received at least two prior systemic therapies. FDA granted accelerated approval for FL and SLL based on overall response rate. 

"We have been eagerly awaiting the approval of this therapy as these are patients for whom there are few other good treatment options," said Lee Greenberger, Ph.D., LLS's chief scientific officer. "LLS funded research contributed to the understanding of the PI3K pathway in B cell malignancies beginning in 1999; this allowed the identification and clinical development of inhibitors of this target. LLS exists to find cures and ensure access to treatments for blood cancer patients, and any new advance that brings the potential to help save more lives is good news."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

Contact: Andrea Greif
Senior Director of Communications
(914)821-8958 (p)
914)772-3027 (c)
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
2. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
3. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
4. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
5. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
6. New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
7. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
8. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
9. Polaris Group Files New IND for ADI-PEG 20 in Leukemia
10. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
11. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... WILLIAMSTON, Mich. , July 13, 2017  Centurion Medical Products, ... offers its DisImpactor ® fecal impaction removal device for hospice ... ... Patient pain management ... DisImpactor for Hospice can help alleviate patient pain while preventing unneeded ...
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... Theater of Witness , was awarded a $300,000 grant from The Pew ... fosters empathy, comfort with ambiguity and the recognition of one’s own limits among ...
(Date:7/21/2017)... ... 2017 , ... The Margarian Law Firm has filed a class action ... for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ... alleges Canada Dry Ginger Ale claims on its bottle that it is made from ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... CA (PRWEB) , ... July 21, 2017 , ... West ... “Tu” Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West ... 27 years of experience in dermatology, skin cancer , and more. She graduated ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians ... on the rise, say researchers presenting their work at the American Orthopaedic ... “The combination of evaluating the patterns of change in concussion symptom presentation, diagnostic ...
Breaking Medicine News(10 mins):